Which has preferable earnings & valuation, PGNY or HNGE?

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.31B 1.52 $58.52M $0.92 28.22 Hinge Health $720.06M 9.60 -$528.26M $1.28 66.92

Is PGNY or HNGE more profitable?

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% Hinge Health 15.15% 51.60% 14.16%

Does the media favor PGNY or HNGE?

In the previous week, Hinge Health had 3 more articles in the media than Progyny. MarketBeat recorded 7 mentions for Hinge Health and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat Hinge Health's score of 0.50 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PGNY or CHE?

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.31B 1.52 $58.52M $0.92 28.22 Chemed $2.53B 2.76 $265.24M $19.91 26.87

Is PGNY or CHE more profitable?

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% Chemed 10.60% 31.77% 18.90%

Does the media prefer PGNY or CHE?

In the previous week, Progyny and Progyny both had 4 articles in the media. Chemed's average media sentiment score of 1.81 beat Progyny's score of 1.25 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, PGNY or HIMS?

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.31B 1.52 $58.52M $0.92 28.22 Hims & Hers Health $2.35B 3.18 $128.37M -$0.63 N/A

Does the media prefer PGNY or HIMS?

In the previous week, Hims & Hers Health had 33 more articles in the media than Progyny. MarketBeat recorded 37 mentions for Hims & Hers Health and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat Hims & Hers Health's score of 0.21 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, RDNT or PGNY?

Progyny has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.97 -$18.65M -$0.27 N/A Progyny $1.31B 1.52 $58.52M $0.92 28.22

Is RDNT or PGNY more profitable?

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.93% 2.61% 0.91% Progyny 6.00% 15.98% 10.65%

Does the media refer more to RDNT or PGNY?

In the previous week, RadNet had 1 more articles in the media than Progyny. MarketBeat recorded 5 mentions for RadNet and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat RadNet's score of 1.12 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LFST or PGNY?

In the previous week, LifeStance Health Group had 7 more articles in the media than Progyny. MarketBeat recorded 11 mentions for LifeStance Health Group and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat LifeStance Health Group's score of 0.67 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeStance Health Group 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Progyny (PGNY) Competitors

$25.96 +0.43 (+1.68%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$26.16 +0.20 (+0.78%)

As of 04:00 AM Eastern

Compare

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

Should you buy Progyny stock or one of its competitors? Progyny's main competitors and comparable companies include Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), RadNet (RDNT), and LifeStance Health Group (LFST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Progyny compare to Hinge Health?

Progyny (NASDAQ:PGNY) and Hinge Health (NYSE:HNGE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Hinge Health had 3 more articles in the media than Progyny. MarketBeat recorded 7 mentions for Hinge Health and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat Hinge Health's score of 0.50 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.31B	1.52	$58.52M	$0.92	28.22
Hinge Health	$720.06M	9.60	-$528.26M	$1.28	66.92

94.9% of Progyny shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 18.9% of Hinge Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Progyny currently has a consensus price target of $34.36, suggesting a potential upside of 32.37%. Hinge Health has a consensus price target of $100.57, suggesting a potential upside of 17.41%. Given Progyny's stronger consensus rating and higher probable upside, equities analysts clearly believe Progyny is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Hinge Health	15.15%	51.60%	14.16%

Summary

Hinge Health beats Progyny on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to Chemed?

Progyny (NASDAQ:PGNY) and Chemed (NYSE:CHE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Chemed	10.60%	31.77%	18.90%

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.31B	1.52	$58.52M	$0.92	28.22
Chemed	$2.53B	2.76	$265.24M	$19.91	26.87

Progyny has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

94.9% of Progyny shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 3.3% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Progyny presently has a consensus price target of $34.36, indicating a potential upside of 32.37%. Chemed has a consensus price target of $530.75, indicating a potential downside of 0.78%. Given Progyny's stronger consensus rating and higher possible upside, analysts plainly believe Progyny is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Progyny and Progyny both had 4 articles in the media. Chemed's average media sentiment score of 1.81 beat Progyny's score of 1.25 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Chemed beats Progyny on 9 of the 16 factors compared between the two stocks.

How does Progyny compare to Hims & Hers Health?

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.31B	1.52	$58.52M	$0.92	28.22
Hims & Hers Health	$2.35B	3.18	$128.37M	-$0.63	N/A

Progyny has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market.

94.9% of Progyny shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Hims & Hers Health had 33 more articles in the media than Progyny. MarketBeat recorded 37 mentions for Hims & Hers Health and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat Hims & Hers Health's score of 0.21 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	11 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny has a net margin of 6.00% compared to Hims & Hers Health's net margin of -5.51%. Progyny's return on equity of 15.98% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Progyny presently has a consensus target price of $34.36, indicating a potential upside of 32.37%. Hims & Hers Health has a consensus target price of $32.43, indicating a potential upside of 1.51%. Given Progyny's stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Summary

Progyny beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to RadNet?

RadNet (NASDAQ:RDNT) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

In the previous week, RadNet had 1 more articles in the media than Progyny. MarketBeat recorded 5 mentions for RadNet and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat RadNet's score of 1.12 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet currently has a consensus target price of $88.00, indicating a potential upside of 14.21%. Progyny has a consensus target price of $34.36, indicating a potential upside of 32.37%. Given Progyny's higher possible upside, analysts plainly believe Progyny is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

RadNet has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Progyny has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.93%	2.61%	0.91%
Progyny	6.00%	15.98%	10.65%

77.9% of RadNet shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 5.1% of RadNet shares are owned by insiders. Comparatively, 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Progyny has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.97	-$18.65M	-$0.27	N/A
Progyny	$1.31B	1.52	$58.52M	$0.92	28.22

Summary

Progyny beats RadNet on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

LifeStance Health Group currently has a consensus target price of $12.38, suggesting a potential downside of 2.17%. Progyny has a consensus target price of $34.36, suggesting a potential upside of 32.37%. Given Progyny's stronger consensus rating and higher probable upside, analysts clearly believe Progyny is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, LifeStance Health Group had 7 more articles in the media than Progyny. MarketBeat recorded 11 mentions for LifeStance Health Group and 4 mentions for Progyny. Progyny's average media sentiment score of 1.25 beat LifeStance Health Group's score of 0.67 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeStance Health Group	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has lower revenue, but higher earnings than LifeStance Health Group. Progyny is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	3.44	$9.66M	$0.13	97.31
Progyny	$1.31B	1.52	$58.52M	$0.92	28.22

LifeStance Health Group has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Progyny has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Progyny has a net margin of 6.00% compared to LifeStance Health Group's net margin of 3.19%. Progyny's return on equity of 15.98% beat LifeStance Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	3.19%	3.39%	2.33%
Progyny	6.00%	15.98%	10.65%

85.5% of LifeStance Health Group shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 3.5% of LifeStance Health Group shares are held by insiders. Comparatively, 9.9% of Progyny shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Progyny beats LifeStance Health Group on 11 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.96B	$9.76B	$7.36B	$12.86B
Dividend Yield	N/A	2.54%	2.54%	10.68%
P/E Ratio	28.22	34.12	268.94	24.05
Price / Sales	1.52	4.93	629.33	95.10
Price / Cash	34.68	127.49	78.13	53.57
Price / Book	4.39	3.96	13.07	6.15
Net Income	$58.52M	$311.06M	$3.46B	$347.39M
7 Day Performance	-1.22%	-0.11%	1.10%	-0.86%
1 Month Performance	-19.48%	-0.43%	3.99%	1.13%
1 Year Performance	12.24%	16.32%	26.52%	19.65%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	4.597 of 5 stars	$25.96 +1.7%	$34.36 +32.4%	+15.1%	$1.96B	$1.31B	28.22	310	Positive News Analyst Forecast Gap Up
HNGE Hinge Health	3.7256 of 5 stars	$87.79 -0.8%	$100.57 +14.6%	+49.5%	$7.14B	$720.06M	68.59	1,437
CHE Chemed	4.0658 of 5 stars	$524.60 -1.6%	$530.75 +1.2%	+17.3%	$6.96B	$2.53B	26.35	15,811	Positive News
HIMS Hims & Hers Health	1.9399 of 5 stars	$28.50 +1.2%	$32.43 +13.8%	-26.5%	$6.57B	$2.35B	N/A	2,442	Trending News Insider Trade
RDNT RadNet	3.1618 of 5 stars	$75.93 -0.6%	$88.00 +15.9%	+12.3%	$6.01B	$2.04B	N/A	11,264	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Progyny compare to Hinge Health?

Summary

How does Progyny compare to Chemed?

Summary

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to RadNet?

Summary

How does Progyny compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Progyny compare to Hinge Health?

Does the media favor PGNY or HNGE?

Which has more volatility and risk, PGNY or HNGE?

Which has preferable earnings & valuation, PGNY or HNGE?

Do insiders and institutionals hold more shares of PGNY or HNGE?

Do analysts rate PGNY or HNGE?

Is PGNY or HNGE more profitable?

Summary

How does Progyny compare to Chemed?

Is PGNY or CHE more profitable?

Which has better earnings & valuation, PGNY or CHE?

Which has more risk & volatility, PGNY or CHE?

Do institutionals & insiders believe in PGNY or CHE?

Do analysts prefer PGNY or CHE?

Does the media prefer PGNY or CHE?

Summary

How does Progyny compare to Hims & Hers Health?

Which has stronger valuation & earnings, PGNY or HIMS?

Which has more risk and volatility, PGNY or HIMS?

Do institutionals & insiders have more ownership in PGNY or HIMS?

Does the media prefer PGNY or HIMS?

Is PGNY or HIMS more profitable?

Do analysts recommend PGNY or HIMS?

Summary

How does Progyny compare to RadNet?

Does the media refer more to RDNT or PGNY?

Do analysts rate RDNT or PGNY?

Which has more volatility and risk, RDNT or PGNY?

Is RDNT or PGNY more profitable?

Do insiders and institutionals believe in RDNT or PGNY?

Which has preferable valuation & earnings, RDNT or PGNY?

Summary

How does Progyny compare to LifeStance Health Group?

Do analysts prefer LFST or PGNY?

Does the media refer more to LFST or PGNY?

Which has preferable earnings & valuation, LFST or PGNY?

Which has more risk and volatility, LFST or PGNY?

Is LFST or PGNY more profitable?

Do insiders & institutionals have more ownership in LFST or PGNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools